PO.TB10.05 · 肿瘤生物学

衰老诱导的IL-11增加通过髓系细胞极化导致黑色素瘤中的免疫逃逸和PD-1抵抗

Aged-induced increases in IL-11 leads to immune escape and PD-1 resistance in melanoma through myeloid cell polarization

编号 2080 展板 10 时间 4/20 09:00–12:00 区域 Section 26 主讲 Michael Emmons, BS;PhD
分会场 Aging and Host Determinants of Tumor Progression: The Macroenvironmental Axis
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Michael F. Emmons1, Chao Zhang1, ethan vallebuona1, Richard L. Bennett2, Manali Phadke1, Jonathan D. Licht2, Keiran Smalley1

1Moffitt Cancer Center, Tampa, FL,2University of Florida, Gainesville, FL

摘要 Abstract

中文摘要
背景:与缺氧、药物治疗和衰老相关的应激样状态可通过尚不明确的机制促成癌症中的免疫逃逸。IL-11是一种研究较少的细胞因子,其表达随年龄增加。在先前的工作中,我们鉴定组蛋白去乙酰化酶(HDAC)-8为一种表观遗传调控因子,其表达在多种应激下增加。在此,我们鉴定HDAC8为IL-11表达的调控因子,导致黑色素瘤中的免疫逃逸和免疫治疗抵抗。 目的:我们研究了IL-11在调节免疫微环境中的作用,及其对年轻与衰老小鼠中黑色素瘤进展和免疫治疗抵抗的影响。 方法:对内在敏感和抵抗的黑色素瘤细胞通过细胞因子阵列和ELISA检测细胞因子分泌。使用ATAC-seq、ChIP-seq和scRNA-seq评估过表达HDAC8的人黑色素瘤细胞中IL-11的染色质可及性、组蛋白修饰和转录变化。采用ELISA、免疫组织化学(IHC)和流式检测来评估IL-11表达及其对年轻与衰老小鼠中髓源性抑制细胞(MDSC)和T细胞相互作用的影响。用IL-11阻断抗体和/或抗PD-1抗体处理年轻(<3M)和老年(>18M)小鼠以确定药物疗效。对患者的TMA和IHC进行IL-11染色。 结果:IL-11表达在黑色素瘤细胞中因缺氧以及内在和获得性靶向治疗而上调。IL-11的表达在体内加速黑色素瘤生长,并导致PMN-MDSC积累增加和CD8+ T细胞浸润减少。IL-11表达降低了黑色素瘤模型中抗PD-1治疗的疗效,而IL-11阻断增强了抗PD-1应答。与年轻小鼠(<3M)相比,老年小鼠(>18M)具有更高的循环IL-11水平,以及肝中IL-11表达增加。治疗性阻断IL-11使衰老黑色素瘤小鼠对抗PD-1产生完全的抗肿瘤应答。在黑色素瘤患者样本中,IL-11表达与年龄增加相关,并在CD8+ T细胞浸润减少的肿瘤区域中呈空间表达。 结论:IL-11通过增加PMN-MDSC积累和抑制T细胞识别和浸润,在衰老小鼠中促进一种"冷"免疫微环境。在衰老小鼠中阻断IL-11有助于提高免疫治疗疗效。靶向IL-11代表了一种有前景的治疗策略,可限制免疫逃逸并增强黑色素瘤中对抗PD-1的应答,尤其是在衰老患者中。
查看英文原文 English abstract
Background: Stress-like states, associated with hypoxia, drug treatment and aging, can contribute to immune escape in cancer through mechanisms that remain poorly understood. IL-11 is a poorly studied cytokine whose expression increases with age. In previous work, we have identified histone deacetylase (HDAC)-8, as an epigenetic regulator whose expression increases in response to multiple stresses. Here, we identify HDAC8 as a regulator of IL-11 expression, leading to immune escape and immunotherapy resistance in melanoma. < strong>Objectives: We investigated the role of IL-11 in modulating the immune microenvironment and its impact on melanoma progression and resistance to immunotherapy in young vs aged mice. Methods: Intrinsically sensitive and resistant melanoma cells were assayed for cytokine secretion by cytokine arrays and ELISAs. Chromatin accessibility, histone modifications, and transcriptional changes of IL-11 were assessed in human melanoma cells overexpressing HDAC8 using ATAC-seq, ChIP-seq, and scRNA-seq. ELISA, immunohistochemistry (IHC), and flow assays were employed to evaluate IL-11 expression and its effects on myeloid-derived suppressor cells (MDSCs) and T cell interactions in young vs aged mice. Young (<3M) and old (>18M) mice were treated with an IL-11 blocking antibody and/or anti-PD-1 antibody to determine drug efficacy. TMAs and IHCS from patients were stained for IL-11. Results: IL-11 expression was upregulated in melanoma cells in response to hypoxia as well as intrinsic and acquired targeted therapy treatment. Expression of IL-11 accelerated melanoma growth in vivo and led to increased accumulation of PMN-MDSCs and reduced CD8+ T cell infiltration. IL-11 expression reduced the efficacy of anti-PD-1 therapy in melanoma models, whereas IL-11 blockade enhanced anti-PD-1 responses. Old mice (>18M) had increased circulating levels of IL-11 levels compared to young mice (<3M), as well as increased IL-11 expression in the liver. Therapeutic blockade of IL-11 led to complete anti-tumor responses to anti-PD-1 in aged mice with melanomas. In melanoma patient samples, IL-11 expression was correlated with increased age, and was spatially expressed in areas of the tumor that had reduced CD8+ T cell infiltrate. Conclusions: IL-11 promotes a "cold" immune microenvironment in aged mice by increasing accumulation of PMN-MDSCs and suppressing T cell recognition and infiltration. Blocking IL-11 in aged mice contributed to increased immunotherapy efficacy. Targeting IL-11 represents a promising therapeutic strategy to limit immune escape and boost responses to anti-PD-1 in melanoma, particularly in aged patients.
利益披露 Disclosure
M. F. Emmons, None.. C. Zhang, None.. E. vallebuona, None.. M. Phadke, None.. K. Smalley, None.

← 返回 AACR 2026 检索